Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > I read about increased short volume….not a good place

<< Previous

Bullboard Posts

Next >>

Comment by Goldnboy1on Jul 05, 2023 11:03am

242 Views

Post# 35527304

RE:I read about increased short volume….not a good place

The shorts better cover fast.

Rumour is Car-T Cell program killed cancer in 100% of test subjects. Updates are expected very soon. Any week now.

$ONC's Car-T cell program is aimed at solid state rumours which make up 90% of all cancers.

Car-T cells have only been invented for blood cancers to date. If $ONC has cracked the solid tumour market. This isn't going to be a few billion dollar stock one day. It's going to be a tens of billion dollar stock one day!

For more info on Car-T cells. Watch National Geographic'a "Breakthrough - Curing Cancer" on Disney+.

<< Previous

Bullboard Posts

Next >>

UniDoc brings AI-powered H3 Health Cube to Italy